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Abstract The role played by the polymorphism located
in Toll-like Receptor 9 (TLR9) as a risk factor of cervical
cancer remains elusive. Therefore, we studied the associ-
ation of the TLR9 -1486 T/C (rs187084) and C2848T
(rs352140) polymorphisms with cervical cancer. The TLR9
-1486 T/C and C2848T polymorphism was genotyped in
426 patients and 460 unrelated healthy females from the
Polish population. Logistic regression analysis adjusting
for age, pregnancy, oral contraceptive use, tobacco smok-
ing, and menopausal status showed that both the TLR9
-1486 T/C and C2848T polymorphisms could be a genetic
risk factor for cervical cancer. For the TLR9 -1486 T/C
polymorphism, the adjusted OR for patients with the C/T
genotype versus T/T genotype was 1.371 (95 % CI
1.021–1.842, p = 0.0361), the adjusted OR for the C/C
genotype vs the T/T genotype was 1.300 (95 % CI
1.016–1.507, p = 0.0096), and the adjusted OR for the C/T
or C/C genotype vs the T/T genotype was 1.448 (95 % CI
1.099–1.908, p = 0.0083). For the C2848T polymorphism,
the adjusted OR for patients with the C/T genotype vs C/C
genotype was 1.443 (95 % CI 1.019–2.043, p = 0.0380),
the adjusted OR for the T/T genotype vs the C/C genotype
was 1.237 (95 % CI 1.016–1.507, p = 0.0328), and the
adjusted OR for the T/C or T/T genotype vs the C/C
genotype was 1.345 (95 % CI 0.976–1.855, p = 0.0700).
Our studies suggest that the TLR9 -1486 T/C and C2848T
polymorphisms may be a genetic risk factor for cervical
cancer.
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Introduction
Cervical carcinogenesis is a multi-step process associated
with refractory infection by high-risk human papillomavi-
rus (HPV) types [1, 2]. This includes the transformation of
normal cervical epithelium to cervical intraepithelial neo-
plasia (CIN), which is transformed to invasive cervical
carcinoma [1, 2]. The HPV oncoproteins E6 and E7 play a
key role in cervical carcinogenesis via the disturbance of
apoptosis, the cell cycle, and adaptive immune surveillance
[3]. Only a minority of HPV infected women will develop
CIN or cervical cancer, suggesting that HPV is not a suf-
ﬁcient separate factor responsible for tumorigenesis of the
cervix [4]. Many epidemiological studies have also indi-
cated that environmental factors, contraceptive use,
smoking, and genetic factors may also contribute to cer-
vical carcinogenesis [5–9].
Recently, several studies have demonstrated that HPV
infections may change the expression of toll-like receptors
(TLRs), which interferes with TLRs signaling during early
and late malignant transformation of the cervix [10–13].
TLRs recognize exogenous pathogen-associated molecular
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immune response [14].
In humans, the family of TLRs includes ten members,
which can be divided based on their localization in the cell
[14]. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are
usually situated on the cell surface, whereas TLR3, TLR7,
TLR8, and TLR9 are localized almost exclusively in en-
dosomes [14–17]. TLR9 have been shown to recognize
unmethylated cytosine–phosphate–guanine (CpG) dinu-
cleotide motifs located in bacterial, viral and fungal DNA
[17, 18]. TLR9 is present in macrophages, dendritic cells
and intestinal epithelium, as well as respiratory epithelial
and keratinocytes cells [16, 17, 19–21]. It has been dem-
onstrated that the -1486 T/C (rs187084), -1237T/C
(rs5743836) and C2848T (rs352140) polymorphisms of
TLR9 located in the same block of linkage disequilibrium
(LD) may change TLR9 expression (HapMap CEU data
http://hapmap.ncbi.nlm.nih.gov/)[ 22–24].
There are two studies on the association of the TLR9
1486 T/C (rs187084) and C2848T (rs352140) polymor-
phisms with cervical cancer in various populations, how-
ever, the results are inconsistent [25, 26]. Therefore, we
aimed to study whether TLR9 -1486 T/C (rs187084) and
C2848T (rs352140) can be a genetic risk factor of cervical
cancer in the Polish population.
Patients and methods
Patients and controls
The patient group was composed of 426 women with his-
tologically determined cervical carcinoma according to the
International Federation of Gynecology and Obstetrics
(FIGO). All women were enrolled between April 2007 and
July 2011 at the Department of Radiotherapy, Greater
Poland Cancer Center in Poznan, Poland (Table 1). The
controls included four hundred sixty unrelated healthy
female volunteers who were matched by age to the patients
(Table 1). Information about pregnancy, oral contraceptive
use, tobacco smoking, and menopausal status was obtained
as part of the patient history. Patients and controls were
Caucasian, enrolled from the Wielkopolska area of Poland.
All subjects provided written informed consent. The study
was approved by the Local Ethical Committee of Poznan
University of Medical Sciences.
Genotyping
DNA was obtained from peripheral leucocytes using a stan-
dard salting out procedure. Identiﬁcation of the TLR9 -1486
T/C (rs187084) and C2848T (rs352140) polymorphic variant
was performed by polymerase chain reaction-restriction
fragment length polymorphism (PCR–RFLP). PCR was
conducted employing primer pair 50TTCATTCATTCAGCC
TTCACTCA 30,5 0 GAGTCAAAGCCACAGTCCAC
A3 0 and 50 GCAGCACCCTCAACTTCACC 30and 50 GGC
TGTGGATGTTGTTGTGG 30,r e s p e c t i v e l y .
The PCR-ampliﬁed fragments 565 bp in length bearing
the TLR9 -1486 T/C (rs187084) polymorphism were
digested with restriction enzyme Aﬂ II (C/TTAAG) New
England BioLabs, (Ipswich, USA). The TLR9 T allele was
cleaved into 416 and 149 bp fragments, whereas the TLR9
C allele remained uncut. The PCR-ampliﬁed fragments
360 bp in length corresponding to the TLR9 C2848T
Table 1 Clinical and demographic characteristics of patients and
controls
Characteristic Patients (n = 426)
(%)
Controls (n = 460)
(%)
aMean age
(years) ± SD
51.8 ± 9.7 51.9 ± 9.8
Tumor stage
IA 55 (12.9)
IB 57 (13.4)
IIA 56 (13.1)
IIB 47 (11.0)
IIIA 143 (33.6)
IIIB 54 (12.7)
IVA 8 (1.9)
IVB 6 (1.4)
Histological grade
G1 77 (18.1)
G2 133 (31.2)
G3 94 (22.1)
Gx 122 (28.6)
Histological type
Squamous cell
carcinoma
361 (84.8)
Adenocarcinoma 50 (11.7)
Other 15 (3.5)
Pregnancy
Never 45 (10.6) 51 (11.1)
Ever 381 (89.4) 409 (88.9)
Oral contraceptive pill use
Never 234 (54.9) 257 (55.9)
Ever 192 (45.1) 203 (44.1)
Tobacco smoking
Never 278 (65.3) 312 (67.8)
Ever 148 (34.7) 148 (32.2)
Menopausal status
Premenopausal 149 (35.0) 175 (41.1)
Postmenopausal 277 (65.0) 285 (61.9)
a Age at ﬁrst diagnosis
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nuclease BstUI (CG/CG) New England BioLabs, (Ipswich,
USA). The TLR9 C allele was cleaved into 227 and 133 bp
fragments, whereas the TLR9 T allele remained uncut.
DNA fragments were separated by electrophoresis on 3 %
agarose gel and visualized by ethidium bromide staining.
The TLR9 1486 T/C and C2848T polymorphism was con-
ﬁrmed by repeated PCR–RFLP. Moreover, the restriction
analysis was conﬁrmed by commercial sequencing analysis.
Statistical analysis
The distribution of genotypes in patients and controls was
examined for deviation from Hardy–Weinberg equilibrium
using exact and log likelihood ratio v
2 tests [http://ihg.
gsf.de/cgi-bin/hw/hwa1.pl]. The polymorphism was tested
for association with cervical cancer using the v
2 test for
trend (ptrend). The v
2 test was employed to examine dif-
ferences in genotypic and allelic distribution between
patients and controls. The odds ratio (OR) and 95 % con-
ﬁdence intervals (95 % CI) were calculated. Unconditional
logistic regression analysis was used to adjust for the effect
of confounders such as age, pregnancy, oral contraceptive
use, tobacco smoking, and menopausal status. A p value of
\0.05 was considered statistically signiﬁcant.
Results
Prevalence of the TLR9 -1486 T/C polymorphism
in women with cervical cancer
There was a higher frequency of the TLR9 CC genotype in
women with cervical cancer compared to healthy
individuals, which was 0.19 and 0.14, respectively
(Table 2). We also found increased TLR9 C/T heterozygote
frequency in patients than in controls, which was 0.48 and
0.44, respectively (Table 2). There was also an increased
TLR9 C allele frequency in patients than in controls, which
was 0.43 and 0.36, respectively (Table 2). The p value of
the v
2 test of the trend observed for the TLR9 -1486 T/C
polymorphism was statistically signiﬁcant
(ptrend = 0.0042). Logistic regression analysis showed a
signiﬁcant contribution of the TLR9 -1486 T/C polymor-
phism to cervical cancer (Table 2). The adjusted OR for
patients with the C/T genotype vs T/T genotype was 1.371
(95 % CI 1.021–1.842, p = 0.0361), the adjusted OR for
the C/C genotype vs the T/T genotype was 1.300 (95 % CI
1.016–1.507, p = 0.0096), and the adjusted OR for the C/T
or C/C genotype vs the T/T genotype was 1.448 (95 % CI
1.099–1.908, p = 0.0083) (Table 2).
Prevalence of the TLR9 C2848T polymorphism
in women with cervical cancer
We observed an increased frequency of the TLR9 TT
genotype in patients than controls, which was 0.26 and
0.22, respectively (Table 2). The TLR9 C/T heterozygote
frequency in women with cervical cancer was also
increased compared to healthy individuals and amounted to
0.54 and 0.51, respectively (Table 2). We also observed a
higher TLR9 T allele frequency in patients then healthy
individuals, which was 0.53 and 0.48, respectively
(Table 2). The p value of the v
2 test of the trend observed
for the TLR9 C2848T polymorphism was statistically sig-
niﬁcant (ptrend = 0.0449). Logistic regression analysis
showed a signiﬁcant association of the TLR9 C2848T
polymorphism with cervical cancer (Table 2). The adjusted
Table 2 Contribution of the TLR9 -1486 T/C (rs187084) and C2848T (rs352140) polymorphisms to cervical cancer
Polymorphism rs no. Genotype Patients
(frequency)
Controls
(frequency)
Odds ratio
(95 % CI)
p
a Adjusted odds ratio
(95 % CI)
b
p
a
21486 T/C rs187084 TT 141 (0.33) 193 (0.42) Referent – Referent –
CT 206 (0.48) 203 (0.44) 1.389 (1.038–1.858) 0.0267 1.371 (1.021–1.842) 0.0361
CC 79 (0.19) 64 (0.14) 1.690 (1.138–2.508) 0.0089 1.300 (1.016–1.507) 0.0096
CT ? CC 285 (0.67) 267 (0.58) 1.461 (1.111–1.922) 0.0066 1.448 (1.099–1.908) 0.0083
Minor allele frequency 0.43 0.36 1.327 (1.096–1.607) 0.0037
C2848T rs352140 CC 87 (0.20) 122 (0.27) Referent – Referent –
CT 230 (0.54) 235 (0.51) 1.372 (0.987–1.909) 0.0594 1.443 (1.019–2.043) 0.0380
TT 109 (0.26) 103 (0.22) 1.484 (1.010–2.181) 0.0441 1.237 (1.016–1.507) 0.0328
CT ? TT 339 (0.80) 338 (0.73) 1.406 (1.028–1.925) 0.0326 1.345 (0.976–1.855) 0.0700
Minor allele frequency 0.53 0.48 1.204 (0.999–1.452) 0.0506
Signiﬁcant results are highlighted in bold font
a v
2 analysis
b ORs were adjusted by age, pregnancy, oral contraceptive use, tobacco smoking, and menopausal status
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123OR for patients with the C/T genotype vs C/C genotype
was 1.443 (95 % CI 1.019–2.043, p = 0.0380), the adjus-
ted OR for the T/T genotype vs the C/C genotype was
1.237 (95 % CI 1.016–1.507, p = 0.0328), and the adjus-
ted OR for the T/C or T/T genotype vs the C/C genotype
was 1.345 (95 % CI 0.976–1.855, p = 0.0700) (Table 2).
Discussion
TLR9 plays a crucial role in pathogen recognition and
activation of innate immunity [15, 18]. Stimulation of
TLR9 activates human B cells and plasmacytoid dendritic
cells, causing T helper-1 type immune responses and
antitumor responses [18, 27–31]. The role of the TLR9
pathway in anticancer treatment has been considered in
animal models and patients with renal carcinoma, malig-
nant melanoma, and non-Hodgkin’s lymphoma [27–31].
Moreover, the signiﬁcance of the TLR9 pathway has been
demonstrated in vaccine treatment of cervical carcinoma in
murine model [28]. Mansilla et al. [28] demonstrated that
intratumoral administration of EDA-HPVE7 fusion protein
in combination with TLR9 ligand CpG-B was able to
eradicate large established cervical tumors.
HPV infects primitive basal keratinocytes; however, its
abundant expression and viral assembly take place only in the
upper layers of the stratum spinosum and granulosum of
squamous epithelia [32]. Keratinocytes bear TLR9, and stim-
ulation of TLR9 may result in the production of a spectrum of
mediatorsinﬂuencingthefunctionofimmunecells[21].Some
studies have suggested that changes occur in TLR9 expression
during cervical carcinogenesis [11, 13]. Recently, Hasimu
et al. (2007) found that the expression of TLR9 can be up-
regulated by HPV16 infection in CIN and in cervical squa-
mous carcinoma cells [11]. They also suggested that TLR9
may play important roles in the development and progression
of CIN and cervical carcinoma [11]. Adding to the above
ﬁndings are those of Hasan et al. [13], who demonstrated that
HPV16 infection of human primary keratinocytes reduced
TLR9 transcription and lead to a functional loss of TLR9-
regulated pathways. This may suggest that polymorphisms of
TLR9thatmodulatetheexpressionofTLR9mayhaveaneffect
on the etiopathogenesis of cervical cancer [33].
We observed a contribution of the TLR9 -1486 T/C
(rs187084) and C2848T (rs352140) polymorphisms to the
risk of cervical cancer in a Polish population. Recent
studies conducted by Chen et al. [25] demonstrated that the
TLR9 -1486 T/C (rs187084) polymorphism, located in the
LD block with rs352140, was associated with a signiﬁ-
cantly increased risk of cervical cancer. In contrast, Pandey
et al. [26] showed that the TT genotype of TLR9 (rs352140)
displayed borderline signiﬁcance in increased risk for
advanced cervical cancer in a North India population.
These differences in the effect of TRL9 polymorphism
on the susceptibility to cervical cancer development
between our and Hindu populations may result from racial
heterogeneity, the size of the studied groups, and the action
of distinct behavioral and environmental factors [33].
To date, the TLR9 C2848T (rs352140) polymorphism
has also been associated with Hodgkin’s lymphoma, peri-
odontitis, ulcerative colitis, and systemic lupus erythema-
tosus [34–37]. The other TLR9 variants have also been
found to be risk factors of atopic eczema, tuberculosis,
Helicobacter pylori-induced gastritis, and rheumatoid
arthritis [38–41]. Moreover, these TLR9 variants may
inﬂuence the clinical course of HIV-1 infection, and the
development of endometrial cancer, osteoarthritis, and
non-Hodgkin lymphoma [42–45].
The role of the rs352140 polymorphism on TLR9
expression has been suggested by Kikuchi et al. [24],who
demonstrated that the TLR9 2848 TT genotype was asso-
ciated with a higher expression of TLR9 and an increased
frequency of IgM ? B cells. It has been believed that
chronic inﬂammation may lead to cancer development and
progression (33). The increased expression of the TLR9
2848 T variant in precursor malignant lesion cells com-
bined with infection by various pathogens might support
inﬂammation and cervical cancer development (33).
Our studies suggest that the C2848T (rs352140) poly-
morphism might be a risk factor of cervical cancer in
Polish women. Our genetic evaluation is the ﬁrst in a
Caucasian cohort; therefore this study should be replicated
in a larger and independent cohort.
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